Spero Therapeutics (SPRO) Accumulated Expenses (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Accumulated Expenses came in at $3.1 million in Q1 2026, down 61.63% YoY from $8.2 million in Q1 2025, and down 43.67% on a QoQ basis from $5.6 million in Q4 2025.
Spero Therapeutics (SPRO) Accumulated Expenses (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Accumulated Expenses data on file, last reported at $3.1 million in Q1 2026.
- Quarterly Accumulated Expenses fell 61.63% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 61.63% YoY) and the FY2025 annual result came in at $5.6 million, down 68.53% from the prior year.
- Accumulated Expenses slipped to $3.1 million in Q1 2026, from $5.6 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $17.7 million in Q4 2024 to a low of $1.7 million in Q2 2023.
- A 5-year average of $7.4 million and a median of $6.6 million in 2023 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 590.02% in 2022, down 75.5% in 2022.
- Tracing SPRO's Accumulated Expenses over 5 years: stood at $5.8 million in 2022, then rose by 13.11% to $6.6 million in 2023, then soared by 170.31% to $17.7 million in 2024, then tumbled by 68.53% to $5.6 million in 2025, then sank by 43.67% to $3.1 million in 2026.
- The last three Accumulated Expenses figures came in at $3.1 million (Q1 2026), $5.6 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.11 Mn |
| Mar 31, 2026 | 3.14 Mn |
| Dec 31, 2025 | 5.58 Mn |
| Sep 30, 2025 | 5.64 Mn |
| Jun 30, 2025 | 6.73 Mn |
| Mar 31, 2025 | 8.19 Mn |
| Dec 31, 2024 | 17.72 Mn |
| Sep 30, 2024 | 15.33 Mn |
| Jun 30, 2024 | 10.01 Mn |
| Mar 31, 2024 | 5.38 Mn |
| Dec 31, 2023 | 6.56 Mn |
| Sep 30, 2023 | 6.56 Mn |
| Jun 30, 2023 | 1.66 Mn |
| Mar 31, 2023 | 8.86 Mn |
| Dec 31, 2022 | 5.80 Mn |
| Sep 30, 2022 | 8.09 Mn |
| Jun 30, 2022 | 2.21 Mn |
| Mar 31, 2022 | 9.06 Mn |
| Dec 31, 2021 | 14.35 Mn |
| Sep 30, 2021 | 11.36 Mn |